Invention Grant
- Patent Title: Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke
-
Application No.: US16263202Application Date: 2019-01-31
-
Publication No.: US11236169B2Publication Date: 2022-02-01
- Inventor: Nelson Ruiz-Opazo , Victoria L. M. Herrera , Francis Joseph Carr
- Applicant: TRUSTEES OF BOSTON UNIVERSITY
- Applicant Address: US MA Boston
- Assignee: TRUSTEES OF BOSTON UNIVERSITY
- Current Assignee: TRUSTEES OF BOSTON UNIVERSITY
- Current Assignee Address: US MA Boston
- Agency: Nixon Peabody LLP
- Agent Ronald I. Eisenstein; Nicole D. Kling
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00

Abstract:
Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.
Public/Granted literature
- US20190153106A1 brANTI-DEspR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE Public/Granted day:2019-05-23
Information query